Haiwang's biological anti-tumor drugs are on the market

Among them, gemcitabine and otilacy potassium are one-half of the anticancer drug s-1, which can inhibit the toxic and side effects of the anticancer drug tegafur More worthy of attention is the use of tegio in the treatment of gastric cancer According to the public information, more than 80% of the chemotherapy cases of advanced gastric cancer in Japan use tegio Domestic tegio capsule has been in rapid volume since it was launched in 2009, with a compound growth rate of 124% in 2010-2012 In 2012, the domestic sales volume is about 446 million yuan, and the terminal scale is expected to be close to 1.4 billion yuan, ranking among the top ten anti-tumor drugs in China In addition to Haiwang biology, Qilu pharmaceutical, Hengrui pharmaceutical and Shandong new era pharmaceutical also have approval documents for the drug Antitumor drugs are the main products of Haiwang biomedical industry The company has developed a number of widely known anti-cancer products On December 4 last year, Haiwang biology received 1.5 million yuan of special science and technology funding allocated by Nanshan District Finance Bureau of Shenzhen City for the company's "research and development of new anti-tumor products and core technologies" project On January 17 this year, the company's small volume injection workshop (anti-tumor drugs) obtained GMP certification On March 5, it was learned from the State Intellectual Property Office that the patent "phenylnitroketone compounds containing stilbene segments and their uses" applied by Shenzhen Haiwang pharmaceutical, a wholly-owned subsidiary of Haiwang biology, was authorized by the State Intellectual Property Office According to the abstract of the patent, the patent can be used for the treatment of mammalian cell hyperplastic diseases, such as cancer, and also as a neuroprotective agent At the same time, the pharmaceutical compositions containing these compounds and their use in the preparation of anti-tumor drugs are also disclosed Industry insiders evaluate that once the patent is granted, it is an exclusive drug, which can only be produced by a company with a patent and has market monopoly In recent years, China has been encouraging pharmaceutical enterprises to make independent innovation and promote industrial upgrading Patent medicine is the symbol that best reflects the independent intellectual property rights and R & D strength of enterprises In addition, the national development and Reform Commission is planning to liberalize the price of some drugs The first category is the drugs authorized by the national patent During the "two sessions", the medical representatives suggested that the state should support the provinces to keep the high bidding price of patented drugs in terms of policies, and at the same time give certain financial support.